Commerzbank Ag Reiterates “Buy” Rating for Qiagen N.V. (QGEN)
Qiagen N.V. (NASDAQ:QGEN)‘s stock had its “buy” rating reaffirmed by stock analysts at Commerzbank Ag in a report issued on Thursday.
QGEN has been the topic of a number of other research reports. DZ Bank AG reaffirmed a “neutral” rating on shares of Qiagen N.V. in a research report on Monday, May 29th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Qiagen N.V. in a research report on Monday, July 31st. Barclays PLC reaffirmed an “overweight” rating and issued a $37.00 target price (up previously from $33.00) on shares of Qiagen N.V. in a research report on Monday, July 17th. BidaskClub downgraded Qiagen N.V. from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Finally, Independent Research GmbH raised Qiagen N.V. from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $33.17.
Shares of Qiagen N.V. (NASDAQ:QGEN) traded down 0.60% during mid-day trading on Thursday, hitting $31.25. The stock had a trading volume of 469,055 shares. Qiagen N.V. has a 12-month low of $24.86 and a 12-month high of $35.26. The stock has a market cap of $7.13 billion, a price-to-earnings ratio of 95.57 and a beta of 1.14. The firm’s 50-day moving average price is $32.99 and its 200 day moving average price is $31.27.
Qiagen N.V. (NASDAQ:QGEN) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.02. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The firm had revenue of $349 million for the quarter, compared to the consensus estimate of $353.09 million. During the same quarter last year, the business posted $0.24 EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Equities analysts forecast that Qiagen N.V. will post $1.22 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/20/commerzbank-ag-reiterates-buy-rating-for-qiagen-n-v-qgen.html.
Large investors have recently modified their holdings of the company. FNY Managed Accounts LLC purchased a new stake in shares of Qiagen N.V. during the first quarter worth about $103,000. Acrospire Investment Management LLC boosted its stake in shares of Qiagen N.V. by 11.7% in the second quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock worth $112,000 after buying an additional 349 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in shares of Qiagen N.V. during the first quarter worth about $114,000. Quadrant Capital Group LLC boosted its stake in shares of Qiagen N.V. by 4.1% in the second quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock worth $183,000 after buying an additional 225 shares in the last quarter. Finally, Rehmann Capital Advisory Group purchased a new stake in shares of Qiagen N.V. during the first quarter worth about $207,000. Institutional investors own 60.07% of the company’s stock.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.